A 48-year-old woman is diagnosed with stage 2 hypertension (BP 160/100 mmHg). Her workup for secondary causes includes serum electrolytes (normal), renal function (eGFR 92 mL/min/1.73m²), 24-hour urine metanephrines (normal), renal artery duplex ultrasound (normal), and thyroid function tests (normal). She is started on antihypertensive therapy. Which of the following investigations is NOT routinely indicated in the initial evaluation of all newly diagnosed hypertensive patients?

Explanation

## Initial Evaluation of Newly Diagnosed Hypertension **Key Point:** The initial workup of hypertension includes assessment for end-organ damage, metabolic comorbidities, and selected secondary causes — but not all patients require imaging for renal artery stenosis. ### Routine Initial Investigations in Hypertension | Investigation | Purpose | Indication | |---|---|---| | **ECG** | Detect LVH, ischemic changes, arrhythmias | **Routine in all patients** | | **Fasting glucose / HbA1c** | Screen for diabetes (major CV risk factor) | **Routine in all patients** | | **Serum creatinine, eGFR** | Assess baseline renal function; detect CKD | **Routine in all patients** | | **Serum electrolytes (Na⁺, K⁺, Cl⁻)** | Baseline; screen for primary hyperaldosteronism | **Routine in all patients** | | **Lipid profile** | Cardiovascular risk stratification | **Routine in all patients** | | **Urinalysis** | Detect proteinuria, hematuria (renal disease) | **Routine in all patients** | | **Renal artery imaging** (Doppler, CTA, MRA) | Exclude renal artery stenosis | **Only if clinical suspicion** (see below) | | **24-hour urine metanephrines** | Exclude pheochromocytoma | **Only if clinical suspicion** | | **Plasma aldosterone-to-renin ratio** | Screen for primary hyperaldosteronism | **Only if hypokalemia or resistant HTN** | ### When to Screen for Renal Artery Stenosis **High-Yield:** Renal artery imaging is **NOT routine** but is indicated when clinical suspicion is high: 1. **Atherosclerotic RAS:** Age > 60, smoking, CAD, peripheral vascular disease, abrupt HTN onset 2. **Fibromuscular dysplasia:** Young women (< 40), abrupt HTN onset, no other risk factors 3. **Resistant hypertension:** BP uncontrolled on ≥ 3 agents at optimal doses 4. **Flash pulmonary edema** without obvious cause 5. **Acute kidney injury** after ACE-I/ARB initiation 6. **Unilateral small kidney** on imaging **Clinical Pearl:** The patient in the stem has normal renal function, normal renal artery duplex, and no clinical features suggesting RAS (no smoking history mentioned, no resistant HTN, no flash pulmonary edema). Renal artery imaging was appropriately performed due to high BP stage, but it is **not a routine screening test** for all newly diagnosed hypertensive patients. **Warning:** Over-investigation for secondary causes delays initiation of antihypertensive therapy. In the absence of clinical clues, extensive screening (especially renal artery imaging) is not cost-effective and is not recommended by major guidelines (ESC, ACC/AHA, Indian guidelines). ### Recommended Routine Baseline Tests (ESC 2021, ACC/AHA 2017) 1. **History and physical examination** — including orthostatic BP, assessment for secondary HTN clues 2. **ECG** — LVH, ischemia 3. **Laboratory tests:** - Serum creatinine, eGFR, urinalysis - Serum electrolytes (Na⁺, K⁺) - Fasting glucose or HbA1c - Lipid profile - Uric acid (optional) 4. **Optional:** Echocardiography if ECG shows LVH or symptoms of heart failure 5. **Selective screening** for secondary causes based on clinical clues (age, family history, resistant HTN, symptoms)